CTN SR

DRUG3 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Adult ADHDAttention Deficit Disorder With Hyperactivity

Phase 1

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

CompletedNCT07253441

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention Deficit Disorder With Hyperactivity

Start: 2024-08-29End: 2024-12-30Updated: 2025-12-11

Phase 2

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

CompletedNCT01939353

Otsuka Pharmaceutical Development & Commercialization, Inc.Adult ADHD

Start: 2013-10-03End: 2014-02-20Updated: 2026-05-19

Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

CompletedNCT02547428

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention Deficit Disorder With Hyperactivity

Start: 2015-08-03End: 2016-06-04Updated: 2021-11-11

Related Papers

Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study

CNS Spectrums2024-10-01